FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3198489974> ?p ?o ?g. }

• W3198489974 endingPage "1329" @default.
• W3198489974 startingPage "1320" @default.
• W3198489974 abstract "Little is known about the consequences of intrauterine exposure to, and the post-natal clearance of, vedolizumab.To investigate the levels of vedolizumab in umbilical cord blood of newborns and rates of clearance after birth, as well as how these correlated with maternal drug levels, risk of infection and developmental milestones during the first year of life METHODS: Vedolizumab-treated pregnant women with inflammatory bowel disease were prospectively recruited from 12 hospitals in Denmark and Canada in 2016-2020. Demographics were collected from medical records. Infant developmental milestones were evaluated by the Ages and Stages Questionnaire (ASQ-3). Vedolizumab levels were measured at delivery and, in infants, every third month until clearance. Non-linear regression analysis was applied to estimate clearance.In 50 vedolizumab-exposed pregnancies, we observed 43 (86%) live births, seven (14%) miscarriages, no congenital malformations and low risk of adverse pregnancy outcomes. Median infant:mother vedolizumab ratio at birth was 0.44 (95% confidence interval [CI], 0.32-0.56). The mean time to vedolizumab clearance in infants was 3.8 months (95% CI, 3.1-4.4). No infant had detectable levels of vedolizumab at 6 months of age. Developmental milestones at 12 months were normal or above average. Neither vedolizumab exposure in the third trimester (RR 0.54, 95% CI, 0.28-1.03) nor combination therapy with thiopurines (RR 1.29, 95% CI, 0.60-2.77) seemed to increase the risk of infections in the offspring.Neonatal vedolizumab clearance following intrauterine exposure is rapid. Infant vedolizumab levels did not correlate with the risk of infections during the first year of life. Continuation of vedolizumab throughout pregnancy is safe." @default.
• W3198489974 created "2021-09-13" @default.
• W3198489974 creator A5003278567 @default.
• W3198489974 creator A5006772486 @default.
• W3198489974 creator A5014540541 @default.
• W3198489974 creator A5017328328 @default.
• W3198489974 creator A5019602506 @default.
• W3198489974 creator A5028542740 @default.
• W3198489974 creator A5030434452 @default.
• W3198489974 creator A5031778278 @default.
• W3198489974 creator A5035386332 @default.
• W3198489974 creator A5042526092 @default.
• W3198489974 creator A5045493973 @default.
• W3198489974 creator A5047967057 @default.
• W3198489974 creator A5049491345 @default.
• W3198489974 creator A5053920924 @default.
• W3198489974 creator A5054104724 @default.
• W3198489974 creator A5062547835 @default.
• W3198489974 creator A5071639839 @default.
• W3198489974 creator A5077279523 @default.
• W3198489974 creator A5082667438 @default.
• W3198489974 creator A5089518876 @default.
• W3198489974 date "2021-09-02" @default.
• W3198489974 modified "2023-10-13" @default.
• W3198489974 title "Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population‐based cohort study" @default.
• W3198489974 cites W2035451762 @default.
• W3198489974 cites W2185850265 @default.
• W3198489974 cites W2252797808 @default.
• W3198489974 cites W2316715874 @default.
• W3198489974 cites W2569803223 @default.
• W3198489974 cites W2597714858 @default.
• W3198489974 cites W2613309961 @default.
• W3198489974 cites W2749957581 @default.
• W3198489974 cites W2760898331 @default.
• W3198489974 cites W2765516464 @default.
• W3198489974 cites W2789263551 @default.
• W3198489974 cites W2801753207 @default.
• W3198489974 cites W2861824477 @default.
• W3198489974 cites W2886879561 @default.
• W3198489974 cites W2910459213 @default.
• W3198489974 cites W2944434778 @default.
• W3198489974 cites W2947052806 @default.
• W3198489974 cites W2986832549 @default.
• W3198489974 cites W3042861029 @default.
• W3198489974 cites W3045204432 @default.
• W3198489974 cites W3082374255 @default.
• W3198489974 cites W3083938121 @default.
• W3198489974 cites W3088164941 @default.
• W3198489974 cites W3092358369 @default.
• W3198489974 cites W3102628359 @default.
• W3198489974 cites W3115550355 @default.
• W3198489974 cites W3186616158 @default.
• W3198489974 doi "https://doi.org/10.1111/apt.16593" @default.
• W3198489974 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34472644" @default.
• W3198489974 hasPublicationYear "2021" @default.
• W3198489974 type Work @default.
• W3198489974 sameAs 3198489974 @default.
• W3198489974 citedByCount "12" @default.
• W3198489974 countsByYear W31984899742022 @default.
• W3198489974 countsByYear W31984899742023 @default.
• W3198489974 crossrefType "journal-article" @default.
• W3198489974 hasAuthorship W3198489974A5003278567 @default.
• W3198489974 hasAuthorship W3198489974A5006772486 @default.
• W3198489974 hasAuthorship W3198489974A5014540541 @default.
• W3198489974 hasAuthorship W3198489974A5017328328 @default.
• W3198489974 hasAuthorship W3198489974A5019602506 @default.
• W3198489974 hasAuthorship W3198489974A5028542740 @default.
• W3198489974 hasAuthorship W3198489974A5030434452 @default.
• W3198489974 hasAuthorship W3198489974A5031778278 @default.
• W3198489974 hasAuthorship W3198489974A5035386332 @default.
• W3198489974 hasAuthorship W3198489974A5042526092 @default.
• W3198489974 hasAuthorship W3198489974A5045493973 @default.
• W3198489974 hasAuthorship W3198489974A5047967057 @default.
• W3198489974 hasAuthorship W3198489974A5049491345 @default.
• W3198489974 hasAuthorship W3198489974A5053920924 @default.
• W3198489974 hasAuthorship W3198489974A5054104724 @default.
• W3198489974 hasAuthorship W3198489974A5062547835 @default.
• W3198489974 hasAuthorship W3198489974A5071639839 @default.
• W3198489974 hasAuthorship W3198489974A5077279523 @default.
• W3198489974 hasAuthorship W3198489974A5082667438 @default.
• W3198489974 hasAuthorship W3198489974A5089518876 @default.
• W3198489974 hasBestOaLocation W31984899742 @default.
• W3198489974 hasConcept C126322002 @default.
• W3198489974 hasConcept C131872663 @default.
• W3198489974 hasConcept C187212893 @default.
• W3198489974 hasConcept C201903717 @default.
• W3198489974 hasConcept C2776207728 @default.
• W3198489974 hasConcept C2778260677 @default.
• W3198489974 hasConcept C2778279030 @default.
• W3198489974 hasConcept C2779134260 @default.
• W3198489974 hasConcept C2779234561 @default.
• W3198489974 hasConcept C2908647359 @default.
• W3198489974 hasConcept C54355233 @default.
• W3198489974 hasConcept C71924100 @default.
• W3198489974 hasConcept C86803240 @default.
• W3198489974 hasConcept C99454951 @default.
• W3198489974 hasConceptScore W3198489974C126322002 @default.
• W3198489974 hasConceptScore W3198489974C131872663 @default.

• next